2017年自身免疫性肝炎及原发性胆汁性胆管炎研究进展

李淑香; 段维佳; 张栋; 尤红; 贾继东

doi:10.3969/j.issn.1001-5256.2018.07.044

2017年自身免疫性肝炎及原发性胆汁性胆管炎研究进展

DOI: 10.3969/j.issn.1001-5256.2018.07.044

首都医科大学附属北京友谊医院肝病研究中心肝硬化转化医学北京市重点实验室国家消化系统疾病临床医学研究中心

基金项目:

北京市科技计划项目(D161100002716003;Z171100002217082)；

详细信息

中图分类号: R575.1;R575.7
计量
- 文章访问数: 2064
- HTML全文浏览量: 55
- PDF下载量: 478
- 被引次数: 0
出版历程
- 收稿日期: 2018-02-22
- 出版日期: 2018-07-20

Research advances in autoimmune hepatitis and primary biliary cholangitis in 2017

Liver Research Center, Beijing Friendship Hospital, Capital Medical University & Beijing Key Laboratory of Translational Medicine in Liver Cirrhosis & National Clinical Research Center for Digestive Diseases

Research funding:

摘要

摘要: 自身免疫性肝病是一组由异常的自身免疫介导的慢性肝损伤,主要包括自身免疫性肝炎、原发性胆汁性胆管炎和原发性硬化性胆管炎等。随着人们对疾病认识及诊疗水平的不断提高,自身免疫性肝病的发病率呈上升趋势,因而越来越受到肝病学专家的重视。2017年,自身免疫性肝炎及原发性胆汁性胆管炎在基础和临床研究方面取得了许多新进展,对这两种疾病在2017年的相关研究进展进行了综述。
- 肝炎,自身免疫性 /
- 原发性胆汁性胆管炎 /
- 综述
Abstract: Autoimmune liver diseases are a group of chronic liver injuries mediated by abnormal autoimmunity and mainly include autoimmune hepatitis ( AIH) , primary biliary cholangitis ( PBC) , and primary sclerosing cholangitis. With the continuous improvement in people's understanding of these diseases and the level of diagnosis and treatment, the incidence of autoimmune liver diseases is constantly increasing and such diseases have been taken more and more seriously by hepatologists. In 2017, new achievements have been made in the basic and clinical research on AIH and PBC, and this article reviews the research advances in these two diseases in 2017.
- hepatitis, autoimmune /
- primary biliary cholangitis /
- review

HTML全文

参考文献(32)

[1]KIM BH, CHOI HY, KI M, et al.Population-based prevalence, incidence, and disease burden of autoimmune hepatitis in South Korea[J].PLo S One, 2017, 12 (8) :e0182391.

[2]de BOER YS, van GERVEN NM, ZWIERS A, et al.Genomewide association study identifies variants associated with autoimmune hepatitis type 1[J].Gastroenterology, 2014, 147 (2) :443-452.e5.

[3]WENG X, HE Y, VISVABHARATHY L, et al.Crosstalk between type II NKT cells and T cells leads to spontaneous chronic inflammatory liver disease[J].J Hepatol, 2017, 67 (4) :791-800.

[4]HUANG J, YUAN Q, ZHU H, et al.IL-17C/IL-17RE augments T cell function in autoimmune hepatitis[J].J Immunol, 2017, 198 (2) :669-680.

[5]QIAN J, MENG Z, GUAN J, et al.Expression and roles of TIPE2in autoimmune hepatitis[J].Exp Ther Med, 2017, 13 (3) :942-946.

[6]HEALEY R, CORLESS L, GORDINS P, et al.Do anti-smooth muscle antibodies predict development of autoimmune hepatitis in patients with normal liver function-A retrospective cohort review[J].Autoimmun Rev, 2016, 15 (7) :668-672.

[7]MURATORI P, EFE C, MURATORI L, et al.Clinical implications of antimitochondrial antibody seropositivity in autoimmune hepatitis:A multicentre study[J].Eur J Gastroenterol Hepatol, 2017, 29 (7) :777-780.

[8]WANG J, MALIK N, YIN M, et al.Magnetic resonance elastography is accurate in detecting advanced fibrosis in autoimmune hepatitis[J].World J Gastroenterol, 2017, 23 (5) :859-868.

[9]PUUSTINEN L, HAKKARAINEN A, KIVISAARI R, et al.31Phosphorus magnetic resonance spectroscopy of the liver for evaluating inflammation and fibrosis in autoimmune hepatitis[J].Scand J Gastroenterol, 2017, 52 (8) :886-892.

[10]BALITZER D, SHAFIZADEH N, PETERS MG, et al.Autoimmune hepatitis:Review of histologic features included in the simplified criteria proposed by the international autoimmune hepatitis group and proposal for new histologic criteria[J].Mod Pathol, 2017, 30 (5) :773-783.

[11]BORSSENAD, PALMQVIST R, KECHAGIAS S, et al.Histological improvement of liver fibrosis in well-treated patients with autoimmune hepatitis:A cohort study[J].Medicine (Baltimore) , 2017, 96 (34) :e7708.

[12]EFE C, HAGSTROM H, YTTING H, et al.Efficacy and safety of mycophenolate mofetil and tacrolimus as second-line therapy for patients with autoimmune hepatitis[J].Clin Gastroenterol Hepatol, 2017, 15 (12) :1950-1956.e1.

[13]PEISELER M, LIEBSCHER T, SEBODE M, et al.Efficacy and limitations of budesonide as a second-line treatment for patients with autoimmune hepatitis[J].Clin Gastroenterol Hepatol, 2018, 16 (2) :260-267.e1.

[14]DESWAL S, SRIVASTAVA A.Role of allopurinol in optimizing thiopurine therapy in patients with autoimmune hepatitis:A review[J].J Clin Exp Hepatol, 2017, 7 (1) :55-62.

[15]HIRSCHFIELD GM, LIU X, XU C, et al.Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants[J].N Engl J Med, 2009, 360 (24) :2544-2555.

[16]KAWASHIMA M, HITOMI Y, AIBA Y, et al.Genome-wide association studies identify PRKCB as a novel genetic susceptibility locus for primary biliary cholangitis in the Japanese population[J].Hum Mol Genet, 2017, 26 (3) :650-659.

[17]QIU F, TANG R, ZUO X, et al.A genome-wide association study identifies six novel risk loci for primary biliary cholangitis[J].Nat Commun, 2017, 8:14828.

[18]ERICE O, MUNOZ-GARRIDO P, VAQUERO J, et al.MicroRNA-506 promotes primary biliary cholangitis-like features in cholangiocytes and immune activation[J].Hepatology, 2018, 67 (4) :1420-1440.

[19]TANG R, WEI Y, LI Y, et al.Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy[J].Gut, 2018, 67 (3) :534-541.

[20]BAE HR, LEUNG PS, TSUNEYAMA K, et al.Chronic expression of interferon-gamma leads to murine autoimmune cholangitis with a female predominance[J].Hepatology, 2016, 64 (4) :1189-1201.

[21]BAE HR, HODGE DL, YANG GX, et al.The interplay of type I and type II interferons in murine autoimmune cholangitis as a basis for sex-biased autoimmunity[J].Hepatology, 2018, 67 (4) :1408-1419.

[22]DAHLQVIST G, GAOUAR F, CARRAT F, et al.Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis[J].Hepatology, 2017, 65 (1) :152-163.

[23]KOWDLEY KV, LUKETIC V, CHAPMAN R, et al.A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis[J].Hepatology, 2018, 67 (5) :1890-1902.

[24]SAMUR S, KLEBANOFF M, BANKEN R, et al.Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis[J].Hepatology, 2017, 65 (3) :920-928.

[25]JONES D, BOUDES PF, SWAIN MG, et al.Seladelpar (MBX-8025) , a selective PPAR-δagonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid:A double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study[J].Lancet Gastroenterol Hepatol, 2017, 2 (10) :716-726.

[26]HEGADE VS, KENDRICK SF, DOBBINS RL, et al.Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis:A double-blind, randomised, placebo-controlled, crossover, phase 2a study[J].Lancet, 2017, 389 (10074) :1114-1123.

[27]HOSONUMA K, SATO K, YAMAZAKI Y, et al.A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia[J].Am J Gastroenterol, 2015, 110 (3) :423-431.

[28]REIG A, SESEP, PARES A.Effects of bezafibrate on outcome and pruritus in primary biliary cholangitis with suboptimal ursodeoxycholic acid response[J].Am J Gastroenterol, 2018, 113 (1) :49-55.

[29]CHEN S, DUAN W, YOU H, et al.A brief review on prognostic models of primary biliary cholangitis[J].Hepatol Int, 2017, 11 (5) :412-418.

[30]YANG F, YANG Y, WANG Q, et al.The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis:The additional effect of anti-gp210[J].Aliment Pharmacol Ther, 2017, 45 (5) :733-743.

[31]CHEUNG KS, SETO WK, FUNG J, et al.Prognostic factors for transplant-free survival and validation of prognostic models in Chinese patients with primary biliary cholangitis receiving ursodeoxycholic acid[J].Clin Transl Gastroenterol, 2017, 8 (6) :e100.

[32]LIN L, PIAO M, JIANG X, et al.Does neutrophil-to-lymphocyte ratio predict 1-year mortality in patients with primary biliary cholangitis?Results from a retrospective study with validation cohort[J].BMJ Open, 2017, 7 (7) :e015304.

施引文献

资源附件(0)

访问统计